Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are featured by chronic intestinal inflammation, which is becoming increasingly prevalent in Western societies, and is spreading to the rest of the world. Although the etiology of IBD is poorly understood, it is widely accepted that several factors may be crucial, which includes genetics, diet and lifestyle, immunity, environment, and microbiota. In the past decade, huge advances have been made toward a better understanding of IBD, epitomized by far-reaching progress in the field of microbiome. In this review, we summarize the current knowledge of how changes in microbiota may affect the pathogenesis of IBD. Commensal bacteria, benign normally, are essentially opportunists that may readily take over, and potentially contributes to dysbiosis, which, in turn, promotes pathogenesis. Several pathogens, mainly Mycobacterium avium paratuberculosis, adherent invasive Escherichia coli, Clostridium difficile, Campylobacter, and Salmonella, have been shown to be associated with IBD, but the causality remains unproven. The microbiome comprises of not only bacteria, but also viruses, bacteriophages, and fungi. However, little is known as per the role of the latter. We highlight recent research on viruses, bacteriophages, and fungi in IBD. We also discuss the progress on manipulating the microflora to serve therapeutic purposes. The methodology for manipulating the microbiota covers fecal transplantation, pre-, pro-, syn- and post-biotics, helminth therapy, bacteriocins, bacteriophage, etc., which greatly enriches the arsenal against IBD. Manipulation of intestinal microbiome represents a promising type of therapy for IBD.

**Abstract**

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are featured by chronic intestinal inflammation, which is becoming increasingly prevalent in Western societies, and is spreading to the rest of the world. Although the etiology of IBD is poorly understood, it is widely accepted that several factors may be crucial, which includes genetics, diet and lifestyle, immunity, environment, and microbiota. In the past decade, huge advances have been made toward a better understanding of IBD, epitomized by far-reaching progress in the field of microbiome. In this review, we summarize the current knowledge of how changes in microbiota may affect the pathogenesis of IBD. Commensal bacteria, benign normally, are essentially opportunists that may readily take over, and potentially contributes to dysbiosis, which, in turn, promotes pathogenesis. Several pathogens, mainly Mycobacterium avium paratuberculosis, adherent invasive Escherichia coli, Clostridium difficile, Campylobacter, and Salmonella, have been shown to be associated with IBD, but the causality remains unproven. The microbiome comprises of not only bacteria, but also viruses, bacteriophages, and fungi. However, little is known as per the role of the latter. We highlight recent research on viruses, bacteriophages, and fungi in IBD. We also discuss the progress on manipulating the microflora to serve therapeutic purposes. The methodology for manipulating the microbiota covers fecal transplantation, pre-, pro-, syn- and post-biotics, helminth therapy, bacteriocins, bacteriophage, etc., which greatly enriches the arsenal against IBD. Manipulation of intestinal microbiome represents a promising type of therapy for IBD.

**Keywords:** Bacteriotherapy; Butyrate-producing bacteria; Dysbiosis; Fecal microbiota transplantation (FMT); Fungi; Inflammation; IBD; Lactic acid bacteria; Lactobacillus; Fructooligosaccharides; Helminth therapy; Microbiome; Microbiota; Metagenomics; Pathogenic bacteria; Probiotics; Virus

**Introduction**

Characterized by redness, tissue swelling, feelings of heat and pain, and loss of function, inflammation is essentially the body's foremost response against detrimental stimuli such as trauma, laceration, infections, irritants, allergy, frostbite, heat shock, hypoxia, etc.[1], which constitutes a critical part of innate immunity. Inflammation is categorized into acute inflammation and chronic inflammation. During acute inflammation, driven by a few signaling cascades, dilation of arterioles increases localized blood flow. Fluid, electrolytes and other blood components accumulate in the interstitium due to permeabilization of the microvasculature. Neutrophils, and possibly some macrophages, infiltrate into the site of injury, which is implemented by the interactions of cell adhesion molecules (CAMs) including selectins and integrins. The duration varies from seconds or minutes, to a few days. If the stimulating agent is not eliminated in the stage of acute inflammation, which is possible upon cellular stress, microbial infection, epithelial barrier malfunction and suboptimal environment, the inflammatory episode proceeds and develops into distinctive conditions, and that is when chronic inflammation occurs [2,3]. Upon injuries mast cells, damaged endothelium, neural synapses, platelets and neighboring cells release cytokines and chemokines to recruit neutrophils, which, together with macrophages, produce TNF-α, IL-1β, IL-6, IL-8, IFNγ, prostaglandins, etc. This triggers the activation of NF-κB, JAK-STAT, p38-MAPK, PI3K-AKT, β-catenin, and JNK pathways [4]. The pathogens are then disposed of by mobilized T-cells and B-cells, accompanied by the release of reactive oxygen species (ROS) and destructive enzymes.

Intestinal inflammation, while retaining all the common features of the aforementioned inflammatory repertoire, displays distinctive pathological landscape due to the specificity of the organ. It may be initiated by physical injuries, viral invasion, bacterial infection, genetic defects, etc. Inflammatory bowel disease (IBD) is an intestinal disorder featured by intermittent outbreaks of inflammatory destruction. There are two major types of IBD, ulcerative colitis (UC) and Crohn’s disease (CD). UC is manifested exclusively in colonic mucosa, whereas CD shows symptoms such as granulomas and intestinal fibrosis throughout all areas of the gastrointestinal (GI) tract [5]. The highest incidence of IBD is in North America and Europe. In the US alone, an estimate of 1.4 million patients is diagnosed as IBD, and rates continue to climb in some other countries in Asia, northern Africa and Oceania [6]. It is generally believed that genetics, immunity, environmental factors, and microbiome all contribute to the pathogenesis of IBD [7]. This review will discuss microbiome and IBD. We summarize the research progress of host-microbe interactions in IBD and illustrate how to manipulate the gut microflora to serve therapeutic purposes.
Gut Microflora and its Physiological Functions

Shape the gut flora

Co-evolution has forged a symbiotic relationship between host and microbiota through millions of years, thereby imposing a delicate balance between immune activation and immune tolerance on the gut [8,9]. As reviewed by O’Hara AM et al., the intestine is adapted to bidirectional host-flora exchange and harbors a diverse bacterial community that is separated from the internal milieu by only a single layer of epithelial cells [10]. The resident microbiota has a collective metabolic activity equal to a virtual organ within an organ [10]. While gut flora mainly live within the intestinal lumen, a tiny portion of the gut microbiota populates the crypts [11].

Bacteria that populate the gut are 10 times greater in sheer number than the eukaryotic human cells, in parallel with a 100 times larger gene pool than the human genome [12]. Intestinal microbes have a luminal concentration of near 0 in stomach to as high as 10^{12} per gram in colon [13]. Mammals get the gut flora established by maternal transmission from birth canal and breast feeding. It is believed that bacterial community is also inherited in the womb [14], with the delivery mode, vaginal or cesarean-section (C-section), conferring distinctive bacterial communities on the neonates. While infants delivered vaginally generally possess microbiome similar to the vaginal microbiome, C-section babies harbor microbiota resembling that of skin surface [15]. The bacterial community is then shaped by early exposure to environment. The contribution of environmental factors, was further corroborated by mouse studies [16]. Turnbaugh et al., conducted a research in lean and obese twins with metagenomic analysis tools [17]. The study involves female monozygotic and dizygotic twin pairs and their mothers. They showed that the twins-mother co-variation is comparable to that between both monozygotic and dizygotic twins at the gene level of gut microbiome. Thus, they concluded that gut microbiome is shared among family members, but that each person’s gut microbial community varies in the specific bacterial lineages present, with a comparable degree of co-variation between adult monozygotic and dizygotic twin pairs [17]. The composition of gut flora is in a sporadic form in infants and eventually undertakes a globally homeostatic composition in adults if there is no therapeutic or accidental intervention [18]. Taken together, these studies suggest that genetic background and environment factors all contribute to the profile of microbiome.

Physiological functions of microbiome

The corporate number of microbial species in human gut is estimated to be 1000 to 1150, with each individual harboring at least 160 [19]. A large portion (38%) of the total gene pool is commonly shared from individual to individual. The “core human microbiome” refers to the central part of microbial gene pool existing in all or most of humans. Now it is increasingly clear that the interindividual similarity is only present at gene and functional level, but not in terms of organismal lineage [16]. The "variable human microbiome" is the microbial genes in a specific cohort of people, which is based on a combination of host factors [20].

To profile the microbiome constituency of human, the "supraorganism", Human Microbiome Project (HMP) and Metaenomics of the Human Intestinal Tract (MetaHIT) Project were launched [21]. Comparative metagenomics unveiled a wide variety of functions fulfilled by gut microbiota which include: i) gleaning indigestible ingredients from food and synthesizing nutritional factors such as vitamins; ii) detoxifying the deleterious xenobiotics, and affecting the host metabolotypes; iii) providing signals for epithelial renewal, maintaining gut integrity; iv) replacement of pathogenic bacteria by colonization resistance; v) secreting anti-microbial products, e.g. bacteriocins and lactic acid; vi) development of a robust systemic and intestinal immune system that is driven by a well-developed gut microbial community; and vii) determining various physiological states such as cardiac size, and behavioral patterns [10,20].

Firmicutes and Bacteroidetes predominate the gut microbiota, followed by Proteobacteria and Actinobacteria, with minor contributors including Verrucomicrobia and Fusobacteria [22]. Bacteroides and Ruminococcus are consistent with enriched intake of animal sources, while a plant-based diet favors Prevotella [23]. Prevotella to Bacteroides ratio constitutes an important index for clinical diagnosis. Butyrate-producing bacteria, including Clostridium groups IV (Faecalibacterium prausnitzii) and XIVA, Roseburia spp., Butyrivibrio, and lactis bacteria (LAB), mainly Lactobacillus and Bilisobacterium, are believed to benefit the host through anti-inflammation, anti-tumorigenesis, and pathogen exclusion [24-26]. There is also a metabolic interplay between LAB and butyrate-producing bacteria due to the ability of the latter to feed on lactate [27].

In summary, gut flora is shaped gradually during the early stage of life and stays status quo in adulthood without dramatic intervention. The physiological repertoire it fulfills involves digestion, nutritional supplementation, detoxification, educating the immune system, behavioral modulation, etc.

Microbiome in IBD

Commensal bacteria and dysbiosis in IBD

Commensal bacteria are mostly opportunistic rather than completely non-pathogenic, which means that they may contribute to the pathogenesis of IBD. IL10<sup>-/-</sup> mice appear healthy under germ-free (GF) conditions, but quickly develop colitis in a specific-pathogen-free (SPF) environment [28]. In axenic IL10<sup>-/-</sup> mice, sterile bacterial lysates compromise the integrity of the intestinal barrier, but fail to initiate sustained inflammation [29]. Candidatus arthromitis, a gram-positive and unculturable species in Clostridium, also known as segmented filamentous bacteria (SFB), commonly adheres to intestinal epithelium, spurs potent immune responses in gut and is under the tight control of IgA [30-33]. As a commensal microbe, SFB has an immune modulatory role in driving Th1 cell maturation, and even Th1 and T regulatory (Treg) responses and promotes the maturation of host mucosal barrier [30,34,35]. The colonization of SFB enhances inflammatory and anti-microbial actions, and improves the resistance against pathogenic bacteria like Citrobacter rodentium in mice [36]. On the other hand, its proinflammatory properties contributes to IBD in SCID mice reconstituted with CD4<sup>+</sup> T cells from healthy BALB/c mice, as manifested by diagnostic indices [37]. Bacteroides fragilis participates in the induction of active mucosal tolerance by producing polysaccharide A (PSA), which stimulates CD4<sup>+</sup> T cells to trans-differentiate into Foxp3<sup>+</sup> Treg cells [38]. Bacteroides infantis and certain blend of Clostridium groups IV and XIVA can lead to comparable responses [39]. Butyrivibrio cassalicola<sub>4</sub> has a protective effect against 2,4,6-trinitrobenzenesulfonic acid (TNBS) - induced colitis [40]. Supernatant from its culture prevents the loss of...
epithelial integrity in Caco-2 cell line [41]. Administration of *F. prausnitzii* induces Treg activation, elevates anti-inflammatory cytokines, strengthens intestinal barrier, and reduces the severity in several colitis models and helps maintain clinical remission in UC patients [42-45]. Lactic acid bacteria (LAB) benefit the hosts in a similar manner [46-50]. It should be noted that several animal models of IBD may not only be dependent on the microbiota. For example, dextran sulfate sodium (DSS) induced colitis is routinely used for IBD research as a chemical-induced model [51].

Human IBD occurs when there is an unfortunate combination of dysbiosis and genetic susceptibility. Dysbiosis is a perturbed condition of microbiota, which manifests from a weakened capacity to counterbalance bacterial constituency and also to withstand the environmental and host brunt. The data support the notion that it is very much accountable for the ever increasing IBD occurrence [52-55]. In IBD, the diversity of microbiome is reduced. Metagenomics revealed a 25% reduction in genes harbored by the disease-affected patients [19]. Some studies show that *Mycobacterium avium paratuberculosis* (MAP), *Clostridium difficile*, *Ruminococcus gnarus*, and adherent invasive *Escherichia coli* (AIEC) are enriched, while *F. prausnitzii*, *Roseburia hominis*, *Lactobacillus*, *Bifidobacterium*, and *Akkermansia*, which is mucin-attachment dependent, are depleted in IBD patients [56,57].

**Pathogenic bacteria associated with IBD**

There is no conclusion whether there are indeed some pathogens playing a causal role in IBD. The most controversial candidates underlying the etiology are *Mycobacterium avium paratuberculosis* (MAP), adherent invasive *Escherichia coli* (AIEC), *C. difficile*, *Campylobacter*, and *Salmonella*. Although therapeutic trials directed against potential causative infectious agents have been unsuccessful to date, it is possible that the studied IBD patients were a heterogeneous population with multiple etiologies for their IBD. Therefore, a potential benefit could not be demonstrated in the subgroups of patients where one organism may have been driving their IBD.

MAP is widespread in drinking water, milk and other dairy products, as well as meat, and is able to survive pasteurization [58,59]. In ruminants, e.g. cattle, MAP infection culminates in Johne’s disease, a granulomatous type of enteritis that resembles human CD [60]. It severely infects intestinal goblet cells, eliciting epithelial damage and inflammation [61]. The presence can be detected in breast milk, blood, intestinal mucosa, and gut biopsies of CD patients [62-65].

Controversies arise as per its role in IBD. MAP-positive incidence appears non-significantly higher in the feces of CD patients than in those of healthy controls [66]. Furthermore, the positive incidence is significantly higher in biopsies of terminal ileum and colon in CD patients than in those from healthy controls [67]. However, counteracting studies are significantly higher in biopsies of terminal ileum and colon in CD patients versus those from healthy controls [66]. Anti-MAP treatment with antibiotics does show short-term benefits in enhancing corticoid-induced remission, but hardly sustains the improvement over a longer course (156 weeks) [72]. MAP/self-cross-reactivity can be detected in CD patients, but not in healthy controls, imposing higher risks of autoimmunity attack, which implies a correlation between MAP and CD at most notwithstanding [73]. There are studies involving UC as well, but the link with MAP is still missing.

AIEC attaches itself to intestinal mucosa with type I pili and long polar fimbiae (LPF) [74,75]. It is structurally adapted to withstand insult from and replicate within in vacuoles of macrophages [76,77]. By promoting TNF-a release from macrophages, or direct interactions with enterocytes, AIEC stimulates enhanced expression of CEACAM6, a molecule for binding of the type I pili, resulting in more AIEC attachment [74]. AIEC inhibits autophagy by triggering NF-kB signaling and subsequent reduction in ATG5 and ATG16L1, eliciting excessive inflammation [78]. Biopsies from CD patients support the implication of AIEC by increased prevalence, abundance, as well as richness, which, however, is not a proof of causation [79].

*Clostridium difficile* infection (CDI) has doubled in occurrence during the period from 1996 to 2003 and is still steadily expanding in the following years in western countries with the development of antibiotic resistance [80-82]. CDI may lead to colectomy and lethality, and has become more severe due to the emergence of BI/NAP1/027, a more virulent strain characterized by enhanced fluoroquinolone resistance, and higher levels of toxins A and B, and binary toxin [83]. The recurrence rate may be as high as 25% within 30 days after metronidazole or vancomycin treatment [84,85]. The symptomatic presentations of CDI and IBD are hardly distinguishable (diarrhea, leukocytosis, hypoalbunemia, and fever) [86,87], and so poses difficulty for pinpoint therapy. Evidence is accumulating on the linking of CDI with IBD flares and relapses, as indicated by 5% to 60% toxin positive rates in the latter [86]. Incidence of CDI is 2.9-, 4.0-, and 2.1-fold of non-IBD controls for IBD, UC and CD patients respectively [88]. Some immunosuppressive drugs administered for IBD treatment double or triple the incidence of CDI (thiopurines, methotrexate, steroids, corticosteroids), while others, e.g. infliximab, do not show such effects (corticosteroids) [89]. Risk factors for CDI in IBD also involve age, antibiotics, hospitalization, etc. [87]. Recently, region-specific and highly sensitive assays cast questions over the prevalence of CDI in IBD, indicating that the correlation may be confined within a subset of patients [90,91]. It remains unclear whether CDI contributes to IBD inflammation or whether IBD patients are just more susceptible to CDI resulting in a secondary inflammatory process related to the infection.

The prevalence of *Campylobacter* species, particularly *C. concisus* and *C. ureolyticus*, is significantly higher in IBD patients than in non-IBD controls [92-96]. The correlation may rest on the microbes that reside in the GI tract. There exists an active interplay between gut flora and *C. concisus* in CD [97]. *C. jejuni* can possibly ruin the intestinal barrier by translocating commensal bacteria, priming chronic inflammation [98,99]. It is easy to confound *Campylobacter jejuni* enterocolitis with IBD, judging from the clinical presentations [100,101].

Infectious triggers are implicated in the onset and reactivation of IBD by epidemiologic and clinical studies. Exposure to non-typhoid *Salmonella* significantly increases the risk for both CD and UC in the first year, followed by a gradually reducing tendency of IBD flare in a 10-year time frame with a progressively narrowing difference compared with non-infected controls [102]. The same study revealed a risk curve correlated with *Campylobacter* for UC that extremely resembles that of *Salmonella*, therefore favoring a non-causal role for both bacteria. Mark et al. argued that the study is ambiguous due to the detection bias, and a failure to take into account the effects of infection on IBD in susceptible population [103]. The notion that *Salmonella* and *Campylobacter* infection predisposes patients to IBD onset is consistent with some other studies linking the infection with IBD pathogenesis [104,105]. However, CD patients exposed to *Salmonella enterica* do not differ in major histological indexes and necessity for various types of treatment from drug administration to
surgery compared with patients not exposed to Salmonella, indicating a lack of correlation between the infection and CD especially in terms of severity [106]. Besides, enterotoxigenic Bacteroides fragilis, Listeria monocytogenes, Aeromonas hydrophila, Chlamydia sp. are enlisted in the bacterial troops associated with IBD as well [87].

Overall, whether pathogenic infection is a sequel or causality of IBD is a topic of ongoing debate. Endeavors on deciphering this complication wind up in 3 hypotheses: i) there is a subset of gut flora that not only triggers, but also persists after the onset of IBD, however, the identification exceeds the capacity of current methodology; ii) the causative agent has been wiped out by the time of disease occurrence; iii) the microbiome is influenced by underlying defects in the mucosal immune system and does not directly cause the inflammation [107].

Viruses, bacteriophages and fungi in IBD

Easily neglected is that the microbiome comprises of not only bacteria, but also viruses, bacteriophages and fungi. In a sharp contrast, the role of the latter in IBD is poorly defined. These organisms are difficult to isolate and study in the context of intestinal inflammation and so modern techniques will have to evolve to study this critical part of the microbiome.

Epstein-Barr virus (EBV) is commonly detected in the GI mucosa with inflammation [108]. It is significantly more prevalent in intestinal tissues of IBD patients than in healthy controls, and more frequently detected in patients with exacerbation than those in remission [109]. Furthermore, EBV may prolong the inflammation in IBD and enhance replication in B-lymphocytes [110]. Intestinal infection of cytomegalovirus (CMV) may contribute to the severity of UC [111], but again it is not clear whether CMV is contributing to IBD inflammation or is acting as an innocent bystander. Patients with IBD have a long-lasting remission and reduced relapse rates with HIV infection, which is possibly related to depletion of CD4 T cells [112,113]. Measles virus was believed to trigger CD upon specific manners of exposure [114,115], which was supported by some researchers, but the persistent infection theory was disproved by PCR, serology and molecular mimicry [116-119]. Infection with murine influenza virus, which resembles those seen in CD [120]. Bacteriophages, predominantly Caudovirales phage, exist in large abundance in gut wash and ileal biopsies of CD patients [121]. The density in gut mucosa may reach 10^6/cm^3, the composition of which substantially underlies dysbiosis and immune responses in IBD [122]. Fungi in gut mostly consist of ascomycetes including Candida, Penicillium, Saccharomyces genera, and various species of basidiomycetes, the diversity of which increases in IBD [123]. Candida, particularly C. albicans, is well adapted to and commonly colonizes all sections of GI tract [124]. The familial CD is shown to be associated with a higher prevalence and abundance of C. albicans [125,126]. Anti-Saccharomyces cerevisiae antibodies (ASCA) which target a conserved cell wall epitope of fungi including C. albicans and S. cerevisiae have been associated with manifestations of CD [127,128]. The prevalence of C. albicans in colonic mucosa is higher in UC patients than in normal controls, therefore the positive serological reactivity can serve as a diagnostic marker [129]. Some studies showed that Candida slows colonic ulcer healing, which could be reversed by anti-fungal treatment, but, again, the causality in IBD remains to be proven [130-132]. Studies of viruses, bacteriophages, and fungi in the cause and progression of IBD are needed.

Clinical Therapies for IBD Through Manipulating Gut Flora

Most care for IBD occurs in the outpatient setting, with hospitalizations reserved for complications including surgery. Traditional treatment of IBD adopts the strategies of anti-inflammation, dietary management, and surgery, and mitigates the symptoms to a certain extent [133]. Despite recent advances in therapy, there continues to be a demand for highly effective and safe therapies for IBD patients. The manipulation of microbiota has the potential to be a therapeutic strategy for IBD. There are various approaches to target the gut flora, including fecal microbiota transplantation (FMT), pre-, pro-, syn- and postbiotics, parasitic worms, diet, etc. [134-136]

Fecal microbiota transplantation

FMT was first recorded in “Zhou Hou Bei Ji Fang”, a medical manual for emergencies, written in 4th-century China, by Ge Hong, a herbal medicine master and alchemist, who successfully saved lives from food poisoning and diarrhea by oral administration of fecal suspension [137]. The therapeutic potential became the public gaze in modern medicine in the early 1900s, followed by a cohort of modern case reports and case series that have revealed significant cure rates [12,138-141]. The notion of FMT is that the normal microbiota in gut defends the GI mucosa against virulent bacteria through competitive exclusion which is called “barrier effect”, and also fermenting and secreting unused energy substrates such as butyrate to train immune system and prevent growth of harmful, pathogenic bacteria [142]. Fecal suspension is prepared with saline, milk or yogurt, and delivered to the patients by nasogastric/nasoduodenal intubation, enema or colonoscopy [137,140]. Meticulous donor screening may alleviate many of the concerns of transmitting infections including HIV, viral hepatitis, CMV, EBV, etc. [140,143].

FMT represents a relatively safe and efficacious method for the treatment of IBD and CDI in clinical practice, but requires additional study. About 92% patients with CDI reported has alleviated or resolved the symptoms after FMT with low incidence of relapses [144]. There are cases reported showing that 76% IBD patients experience overall improvement, with others getting no resolution of the symptoms [144]. However, the effectiveness of FMT in UC and CD is not convincing until therapeutic effects are observed with a larger cohort and longer follow-up. Protocols towards higher resolution are being developed, e.g. serial FMT. Few serious direct or related adverse effects were observed in the operation of FMT although fewer than 10% of patients after FMT reported flatulence, diarrhea, fever, blood stool, etc., which were tolerable and self-limiting [145]. The small number of adverse events that have been reported following FMT procedures can not necessarily be linked to the procedure or transplant itself [146,147]. FMT procedure may not be advised in patients with significant intestinal inflammation.

In clinical practice, fresh stool can be refined by mixing with buffer solution and filtering. The preparation, while containing the full spectrum of microbiota, repeals the offensive odor of the feces. Also, it is supposed to harbor the standardized gut microbiota that a healthy individual carries. The homogenate can be delivered to patients in order to restore the disturbed bacterial community, and also, cryopreserved for long-term use [148].

Clinicians may be able to select bacterial species of interest to get a defined mixture. This method, called "blended bacterial culture",...
dispenses the need to find a standardized fecal sample, and has a manageable formula. In treated patients, fecal bacteriotherapy using bacterial culture showed some therapeutic effects, reestablished the normal gut pattern over the short term and maintained remission for 6 months [149]. However, this method is not a typical clinical procedure and only limited patients were tested. The abilities of the bacterial culture to populate the gut and to cure IBD among larger groups of patients are still open to criticism.

Prebiotics, probiotics, synbiotics and postbiotics

Prebiotics represent a group of carbohydrates that cannot be degraded by the host but can otherwise promote the growth and activity of beneficial bacteria within the GI tract. Probiotics are microbes that bestow the host advantages in maintaining microbiota homeostasis given enough dosage. Probiotic bacteria were originally based on lactic acid bacteria (LAB), and then extended to Bifidobacterium, Escherichia coli Nissle 1917, and Saccharomyces boulardii [150]. They compete against pathogens by taking over the space and sites of binding and rendering the environment unfavorable by lowering the pH, and secreting bacteriocins and chemicals toxic to the harmful bacteria [25,151,152]. Synbiotics stand for a combinatorial use of prebiotics and probiotics if there exists a synergistic benefit, while postbiotics are metabolic products of the probiotics, promoting homeostatic growth of the microbiota.

Some prebiotics are oligosaccharides such as fructooligosaccharides (FOS), xylooligosaccharides (XOS), galactooligosaccharides (GOS), lactosucrose, and polydextrose. Others are plant-based ingredients like inulin, bran, pectin, and konjac mannan. Researchers now focus on effective in reducing CDI recurrence, while Lactobacillus plus Enterotoxigenic E. Coli (ETEC), uropathogenic E.coli, recurrent C. difficile infection (R-CDI), etc. [142]. Unlike traditional antibiotic therapies, which kill most of the microbiota in gut, or novel therapies like FMT, which provides full-spectrum microbiota of stool, bacterial vaccines lead to clearance of IBD associated pathogenic bacteria specifically. As mentioned earlier, there is no evidence that these organisms are causative. Thus, it is unclear how effective vaccines will be for the treatment of IBD. Bacteriocins, anti-microbial peptides produced by bacteria, are widely used as a food additive to intervene gut microbiota by reducing pathogenic microbial population [164,165]. Bacteriophage therapy gradually becomes enticing due to ever exacerbating drug resistance [166].

Genetically engineered bacteria have been developed to produce cytokines and growth factors to help repair tissue damage. The pioneering work of Steidler and colleagues introduced genetically engineered Lactococcus lactis that produces IL-10 to DSS-treated mice, reducing the incidence of colitis by 50% [167]. Another study using weakened Salmonella Typhimurium SL2207 carrying superoxide dismutase and anti-inflammatory peptides showed some benefits in a murine colitis model [168]. Along with this line, Hamady and colleagues constructed a strain of Bacteroides ovatus, an anaerobe that tolerates xylan. The treatment restored epithelial integrity and mitigated the symptoms of colitis. By tropical delivery, the therapeutic dose could be reduced to 0.01-0.1% of that needed for systemic administration [11]. However, there is a gap to transform bench findings to clinical practice.

In summary, manipulation of intestinal microbiome represents a promising type of therapy for IBD, which may lead to long-lasting remission for patients and provides an alternative therapeutic approach. The methodology covers fecal transplantation, pre-, pro-, syn- and post-biotics, helminth therapy, bacteriocins, bacteriophage, etc., which greatly enriches the arsenal against IBD. However, the promise of pharma-biotics is unlikely to be completely fulfilled without a greater understanding of enteric microflora. Elucidating the
molecular details of host-flora interactions is, therefore, a pre-requisite for a "bugs to drugs" program of discovery.

**Future Prospect**

_Dao De jing_, the foundational document of Taoism written by Lao Zi in 500s B.C., once wisely put it, "Everything carries Yin and embraces Yang. In clashing, the two poles of qi unite." As per traditional Chinese medicine theory, disease, by nature, is an imbalance of Yin and Yang that drive human bodies, therefore the conditions can be categorized into: i) Yin excess; ii) Yang excess; iii) overabundant Yin leading to insufficient Yang; iv) overabundant Yang leading to insufficient Yin; v) dual deficiency of Yin and Yang; vi) dual excess of Yin and Yang.

The thoughts well apply to the roles of microbiota in intestinal homeostasis. Unity of opposites constitutes the core rule that arbitrates the fate of the gut. It runs the risks of simplification to group the bacterial community into beneficial and detrimental, albeit it seems so under controlled scenarios. Philosophically speaking, counterbalancing opposites transform mutually provided proper causes. The current success of therapies on IBD rely heavily on the subliminal practice of promoting balanced gut flora, thereby seducing people into a metaphysical perspective that we can define what's "good" and by consuming a lot of the "good" intestinal disorders can be cured, which, however, gradually deviates researchers from the right track. Communicated by the sayings of Lao Zi, "Yin" and "Yang" do not equal to negative and positive as they literally mean, but rather intermingled opposites that present themselves as the best when the other is rising with comparable momentum. That is why probiotics usually label the range of daily dosage on the bottles. In agreement with the majority of peers in GI field, we favor FMT the most, since in all the available therapeutics, it to a great extent restores the interplay among bacterial populations.

It is less likely to come up with more effective measures to reestablish gut homeostasis without an accurate description of the functions of each bacterial group and their relationships with the host and environmental factors. We propose that the function-based grouping is more meaningful than merely taxonomic classification, which is consistent with the superiority of empirical models in clinical trials. It’s based on the same concept that the interindividual similarity is manifested at gene and functional level, accounting for the resilient and refractory nature of microbiome in response to environmental stresses. Diet, lifestyle, innate and adaptive immunity, and the environment are manipulable leverage to rectify the tilted microbial balance.

Genetic defects lead to a dwindling capacity of the hosts to contain the otherwise harmless bacteria from turmoil and pose potent threat to gut robustness. There are more than 163 confirmed genetic risk loci in IBD including the more and more definitive NOD2, ATG16L1, and IL23R, with 110 shared between CD and UC, and most of them display physiological relevance with epithelial barrier, interactions and responses towards gut flora, autophagy, and maladaptive Th17 type adaptive immunity [170,171]. Studies have attempted to address the functions of these genetic loci in shaping intestinal microbiota, and perhaps the specificity of microbial-risk loci association will be the next hot topic in the studies and treatment of IBD. Researchers also attempt to link inflammatory activity with intestinal microbial biomarkers of inflammation, such as serum C-reactive protein levels and fecal calprotectin. The correlation of microbial biomarkers and inflammatory activity is also critical to the choice of treatment strategy and to monitor treatment efficacy in clinical trials.

Additionally, recent studies mainly focus on bacteria in gut microbiota. However, fungal microbiota and how its metabolites impact GI function and contribute to the pathogenesis of IBD are ignored, as well as the effects of viruses, archaea, and phages. Metagenomic analyses of intestinal microbiota suggested such microbes were also required for the development of IBD as an overall increase in fungal diversity was observed in IBD patients. The relationship between these organisms and IBD will no doubt be explored in more detail in the coming years.

With a similar point of view we use to dissect the bacterial community, the essence of the intestinal homeostasis is not only based on the host or the microbiome, but also the interactions and coexistence of them both. Further elucidation of the correlation between intestinal microbiota and IBD may enable the design of artificial stool with a clear formula and an individualized menu for people with a specific genetic background. Manipulation of microbiome suits the concept of counterbalancing, and would show continuous therapeutic promise in future trials.

**Acknowledgements**

We want to thank Yuxia Xia at the Columbia University in the city of New York for helping with editing and proofreading. This work was supported by Swim Across America Pilot Project grant to JS.

**References**

1. Weiss U (2008) Inflammation. Nature 454: 427.
2. Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124: 823-835.
3. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454: 428-435.
4. Khabar KS (2010) Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cell Mol Life Sci 67: 2937-2955.
5. Cohen LB, Nanau RM2, Delzor F3, Neuman MG4 (2014) Biologic therapies in inflammatory bowel disease. Transl Res 163: 533-556.
6. Long MD, Hutless S, Kappelman MD, Khalili H, Kaplan GG, et al. (2014) Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis 20: 398-415.
7. Sartor RB (2011) Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal Immunol 4: 127-132.
8. Cario E (2013) Microbiota and innate immunity in intestinal inflammation and neoplasia. Curr Opin Gastroenterol 29: 85-91.
9. Monteleone G, Caruso R, Pallone F (2014) Targets for new immunomodulation strategies in inflammatory bowel disease. Autoimmun Rev 13: 11-14.
10. O’Hara AM, Shanahan F (2006) The gut flora as a forgotten organ. EMBO Rep 7: 688-693.
11. Barrett KE (2010) Building better bugs to deliver biologics in intestinal inflammation. Gut 59: 427-428.
12. Sha S, Liang J, Chen M, Xu B, Liang C, et al. (2014) Systematic review: faecal microbia transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 39: 1003-1032.
13. Sartor RB, Mazmanian SK (2012) Intestinal Microbes in Inflammatory Bowel Diseases. Am J Gastroenterol Suppl 1: 15-21.

_Citation:_ Jin D, Zhang H, Sun J (2014) Manipulation of Microbiome, a Promising Therapy for Inflammatory Bowel Diseases. J Clin Cell Immunol 5: 234. doi:10.4172/2155-9899.1000234
55. Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, et al. (2014) Western diet induces dysbiosis with increased E coli in CEABC10 mice, alters host barrier function favouring AIEC colonisation. Gut 63: 116-124.

56. Shanahan F (2012) The colonic microbiota and colonic disease. Curr Gastroenterol Rep 14: 446-452.

57. Machiels K, Joossens M, Sabino J, De Preter V, Arjis I, et al. (2013) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63: 1275-1283.

58. Eltholth MM, Marsh VR, Van Winden S, Guitian FJ (2009) Contamination of food products with Mycobacterium avium paratuberculosis: a systematic review. J Appl Microbiol 107: 1061-1071.

59. Abubakar I, Myhill DJ, Hart AR, Lake IR, Harvey I, et al. (2007) A case-control study of drinking water and dairy products in Crohn’s Disease--further investigation of the possible role of Mycobacterium avium paratuberculosis. Am J Epidemiol 165: 776-783.

60. Chacon O, Bermudez LE, Barletta RG (2004) Johnne's disease, inflammatory bowel disease, and Mycobacterium paratuberculosis. Annu Rev Microbiol 58: 329-363.

61. Golan I, Livneh-Kol A, Gonen E, Yagel S, Rosenshine I, et al. (2009) Mycobacterium avium paratuberculosis invades human small-intestinal goblet cells and elicits inflammation. J Infect Dis 199: 350-354.

62. Autschbach F, Eisold S, Hinz U, Zinser S, Linnebacher M, et al. (2005) High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn’s disease. Gut 54: 944-949.

63. Naser SA, Ghobrial G, Romero C, Valentine JF (2004) Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn’s disease. Lancet 364: 1039-1044.

64. Naser SA, Schwartz D, Shafran I (2000) Isolation of Mycobacterium avium paratuberculosis from the blood of milk of Crohn’s disease patients. Am J Gastroenterol 95: 1094-1095.

65. Sechi LA, Scanu AM, Molinotti P, Cannas S, Mura M, et al. (2005) Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn’s disease in Sardinia. Am J Gastroenterol 100: 1529-1536.

66. Tucci A, Tonon F, Castellani L, Sartini A, Roda G, et al. (2011) Fecal detection of Mycobacterium avium paratuberculosis using the IS900 DNA sequence in Crohn’s disease and ulcerative colitis patients and healthy subjects. Dig Dis Sci 56: 2957-2962.

67. Lee A, Griffiths TA, Parab RS, King RK, Dubinsky MC, et al. (2011) Association of Mycobacterium avium subspecies paratuberculosis with Crohn Disease in pediatric patients. J Pediatr Gastroenterol Nutr 52: 170-174.

68. Baksh FK, Finkelstein SD, Ariyanayagam-Baks SM, Swalsky PA, Klein EC, et al. (2004) Absence of Mycobacterium avium subsp. paratuberculosis in the microdissected granulomas of Crohn’s disease. Mod Pathol 17: 1289-1294.

69. Juste RA, Elguezabal N, Garrido JM, Pavon A, Gejo MV, et al. (2008) On the prevalence of M. avium subspecies paratuberculosis DNA in the blood of healthy individuals and patients with inflammatory bowel disease. PLoS One 3: e2537.

70. Ellingson JL, Cheville JC, Brees D, Miller JM, Cheville NF (2003) Absence of Mycobacterium avium subspecies paratuberculosis components from Crohn’s disease intestinal biopsy tissues. Clin Med Res 1: 217-226.

71. Bernstein CN, Blanchard JR, Rawsthorne P, Collins MT (2004) Population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn’s disease and ulcerative colitis. J Clin Microbiol 42: 1129-1135.

72. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, et al. (2007) Two-year combination antibiotic therapy with clarithromycin, rifabutin, and cefazolin for Crohn’s disease. Gastroenterology 132: 2313-2319.

73. Polymeros D, Bogdanos DP, Day R, Arioli D, Vergani D, et al. (2006) Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn’s disease? Gastroenterology 131: 85-96.

74. Barnich N, Darfeuille-Michaud A (2010) Abnormal CEACAM6 expression in Crohn disease patients favors gut colonization and inflammation by adherent-invasive E. coli. Virulence 1: 281-282.

75. Chassaing B, Rollion N, de Vallée A, Salim SY, Prorok-Hamon M, et al. (2011) Crohn disease--associated adherent-invasive E. coli bacteria target mouse and human Peyer’s patches via long polar fimbriae. J Clin Invest 121: 966-975.

76. Bringer MA, Billard E, Glasser AL, Colombel JF, Darfeuille-Michaud A (2012) Replication of Crohn’s disease-associated AIEC within macrophages is dependent on TNF-α secretion. Lab Invest 92: 411-419.

77. Bringer MA, Rollion N, Glasser AL, Darfeuille-Michaud A (2007) The oxidoreductase DsbA plays a key role in the ability of the Crohn’s disease-associated adherent-invasive Escherichia coli strain LF82 to resist macrophage killing. J Bacteriol 190: 4860-4871.

78. Nguyen HT, Dalmaso G2, Müller S, Carrière J2, Sebold F4, et al. (2014) Crohn’s disease-associated adherent-invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology 146: 508-519.

79. Martinez-Medina M, Aldegue X, Lopez-Siles M, Gonzalez-Huix F, Lopez-Olia C, et al. (2009) Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn’s disease. Inflamm Bowel Dis 15: 872-882.

80. Rohlke F, Stollman N (2012) Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol 5: 403-420.

81. Mitchell I, Shroppshire K, Ruel J (2013) Clostridium difficile infection and fecal bacteriotherapy. Gastroenterol Nuts 36: 42-50.

82. Suwantarat N, Bobak DA (2013) Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection: What’s Old Is New Again? Curr Infect Dis Rep 15: 101-103.

83. Kelly CP, Lamont JT (2008) Clostridium difficile--more difficult than ever. N Engl J Med 359: 1932-1940.

84. Kelly CP (2012) Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18 Suppl 6: 21-27.

85. Pop-Vicas A, Neill MA (2008) Clostridium difficile: the increasingly difficult pathogen. Crit Care 12: 114.

86. Reddy SS, Brandt LJ (2013) Clostridium difficile infection and inflammatory bowel disease. J Clin Gastroenterol 47: 666-671.

87. Nitzan O, Elias M, Chazan B, Raz R, Saliba W (2013) Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroenterol 19: 7577-7585.

88. Rodemann JF, Dubberke ER, Reske KA, Seqo da H, Stone CD (2007) Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 5: 339-344.

89. Goodhand JR, Alazawi W, Rampton DS (2011) Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 33: 428-441.

90. Mascole GM, Penders J, Jonkers DM, Wolffs PF, Pierik MJ (2013) Is clostridium difficile associated with relapse of inflammatory bowel disease? results from a retrospective and prospective cohort study in the Netherlands. Inflamm Bowel Dis 19: 2125-2131.

91. Lamoués-Smith ES, Weber S, Rossi RF, Neinstedt LJ, Mosammaparast N, et al. (2013) Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr 57: 293-297.

92. Mikkhopadiya I, Thomson JM, Hansen R, Berry SH, El-Omar EM, et al. (2011) Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS One 6: e21490.

93. Mahendran V, Riordan SM, Grimm MC, Tran TA, Major J, et al. (2011) Prevalence of Campylobacter species in adult Crohn’s disease and the...
preferential colonization sites of Campylobacter species in the human intestine. PLoS One 6: e25417.
94. Boyanova L, Gergova G, Spassova Z, Koumanova R, Yaneva P, et al. (2004) Campylobacter infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease, and other chronic intestinal diseases. Diagn Microbiol Infect Dis 49: 71-74.
95. Man SM, Zhang L, Day AS, Leach ST, Lemberg DA, et al. (2010) Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease. Inflamm Bowel Dis 16: 1008-1016.
96. Zhang L, Man SM, Day AS, Leach ST, Lemberg DA, et al. (2009) Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn's disease. J Clin Microbiol 47: 453-455.
97. Kaaoush NO, Castaño-Rodríguez N, Day AS, Lebermg DA, Leach ST, et al. (2014) Campylobacter concisus and exotoxin 9 levels in paediatric patients with Crohn's disease and their association with the intestinal microbiota. J Med Microbiol 63: 99-105.
98. Kalischuk LD, Buret AG (2010) A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease? Am J Physiol Gastrointest Liver Physiol 298: G1-9.
99. Kalischuk LD, Inglis GD, Buret AG (2009) Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog 1: 2.
100. Quondamcarlo C, Valentini G, Ruggeri M, Forlini G, Fenderico P, et al. (2011) Role of Salmonella enterica exposure in Chilean Crohn's disease. J Med Microbiol 60: 2653-2656.
101. Vanderploeg R, Panaccione R, Ghosh S, Rioux K (2010) Influences of intestinal bacteria in human inflammatory bowel disease. Infect Dis Clin North Am 24: 977-993, ix.
102. Ryan JL, Shen YJ, Morgan DR, Thorne LB, Kenney SC, et al. (2012) Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig Dis Sci 57: 1887-1898.
103. Dimitroulak E, Pittiriga VC, Piparaki ET, Spanakis NE, Tsakris A (2013) Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. Dis Colon Rectum 56: 322-327.
104. Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, et al. (2011) Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol 50: 31-36.
105. Iyer VH, Augustine J, Pulimood AB, Ajampur SS, Ramakrishna BS (2013) Correlation between coinfection with parasites, cytomegalovirus, and Clostridium difficile and disease severity in patients with ulcerative colitis. Indian J Gastroenterol 32: 115-118.
106. N ospai D, René E, Fiasse R, Farahat K, Beaugery L, et al. (1998) Crohn's disease stable remission after human immunodeficiency virus infection. Dig Dis Sci 43: 412-419.
135. Walk ST, Blum AM, Ewing SAS. Weinstock JV, Young VB (2010) Alteration of the murine gut microbiota during infection with the parasitic helminth Heligmosomoides polygyrus. Inflamm Bowel Dis 16: 1841-1849.

136. Elliott DE, Weinstock JV (2012) Where are we on worms? Curr Opin Gastroenterol 28: 551-556.

137. Zhang F, Luo W, Shi Y, Fan Z, Ji G (2012) Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol 107: 1755.

138. EISEMAN B, SILEN W, BASCOM GS, KAUVAR AJ (1958) Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44: 854-859.

139. Schwam A, Sjölin S, Trottestam U, Aronsson B (1984) Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 16: 211-215.

140. van Nood E, Speelman P, Nieuwdorp M, Keller J (2014) Fecal microbiota transplantation: facts and controversies. Curr Opin Gastroenterol 30: 34-39.

141. Brandt LJ, Aroniadis OC (2013) An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 78: 240-249.

142. Borody TJ, Peattie D, Campbell J (2013) Therapeutic potential of the human gastrointestinal microbiome. Drug Research Development 74: 385-392.

143. Landy J, Al-Hassi HO, McLaughlin SD, Walker AW, Ciclitira PJ, et al. (2011) Review article: fecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 34: 409-415.

144. Anderson JL, Edney RJ, Whelan K (2012) Systematic review: fecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 36: 503-516.

145. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, et al. (2013) Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 56: 758-767.

146. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, et al. (2012) Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107: 1079-1087.

147. De Leon LM, Watson JB, Kelly CR (2013) Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 11: 1036-1038.

148. Hamilton MJ, Weigarden AR, Sadowsky MJ, Khoruts A (2012) Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107: 761-767.

149. Petrof EO, Glooor GB, Vanner SJ, Weese SJ, Carter D, et al. (2013) Stool substitute transplant therapy for the eradication of Clostridium difficile infection: RePOOOPulating the gut. Microbiome 1: 3.

150. Martin R, Miquel S, Ulmer J, Kechaou N, Langella P, et al. (2013) Role of commensal and probiotic bacteria in health: a focus on inflammatory bowel disease. Microbiome 12: 71.

151. Vanderpoel C, Yan F, Polk DB (2008) Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 14: 1585-1596.

152. Salminen S, Salminen E (1997) Lactulose, lact acid bacteria, intestinal microecology and mucosal protection. Scand J Gastroenterol Suppl 222: 45-48.

153. Bakker-Zierikzee AM1, Tol EA, Kroes H, Alles MS, Kok FJ, et al. (2006) Faecal SIgA secretion in infants fed on pre- or probiotic infant formula. Pediatr Allergy Immunol 17: 134-140.

154. Whelan K, Quigley EM (2013) Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 29: 184-189.

155. Bondarenko VM, Likhoded VG (2010) [Role of Toll-like receptors in the therapeutic effect of probiotics]. Ekop Klin Gastroenterol : 78-82.

156. Reiff C, Delday M, Rucklidge G, Reid M, Duncan G, et al. (2009) Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 15: 1721-1736.

157. Nagalingam NA, Lynch SV (2012) Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 18: 968-984.

158. Macfarlane S, Macfarlane GT, Cummings JH (2006) Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 24: 701-714.

159. Weinstock JV, Elliott DE (2009) Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis 15: 128-133.

160. Whelan RA, Hartmann S, Rausch S (2012) Nematode modulation of inflammatory bowel disease. Protoplasma 249: 871-886.

161. Ruysers NE, De Winter BY, De Man JG, Loukas A, Pearson MS, et al. (2009) Therapeutic potential of helminth soluble proteins in TNBS-induced colitis in mice. Inflamm Bowel Dis 15: 491-500.

162. Weinstock JV, Elliott DE (2013) Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol 43: 245-251.

163. Schölmerich J (2013) Trichuris suis ova in inflammatory bowel disease. Dig Dis 31: 391-395.

164. Barbosa MS, Todovor SD, Belguessa M, Choiset Y, Rabesona H, et al. (2014) Purification and characterization of the bacteriocin produced by Labococcus sakei MBSa1 isolated from Brazilian salami. J Appl Microbiol 116: 1195-1208.

165. Karpinski TM, Szakadatkiewicz AK2 (2013) Characteristic of bacteriocines and their application. Pol J Microbiol 62: 223-235.

166. Golkar Z, Bagasra O, Pace DG (2014) Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. J Infect Dev Ctries 8: 129-136.

167. Steidler L, Hans W, Schotte L, Obermeier F, et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 290: 1352-1355.

168. Palffy R, Gardlik R, Behuliak M, Jani P, Balakova D, et al. (2011) Salmonella-mediated gene therapy in experimental colitis in mice. Exp Biol Med (Maywood) 236: 177-183.

169. Hamady ZZ, Scott N, Farrar MD, Lodge JP, Holland KT, et al. (2010) Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 59: 461-469.

170. Jostins L, Rius K, Weersma RK, Duerr RH, McGovern DP, et al. (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491: 119-124.

171. Uhlig HH (2013) Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut 62: 1795-1805.